Literature DB >> 26679445

Examining Differences in Opportunity and Eligibility for Cancer Clinical Trial Participation Based on Sociodemographic and Disease Characteristics.

Jessica Rearden1, Alexandra L Hanlon2, Connie Ulrich1, Margo Brooks-Carthon1, Marilyn Sommers1.   

Abstract

PURPOSE/
OBJECTIVES: To examine differences in opportunity and eligibility for cancer clinical trial (CCT) participation based on sociodemographic and disease characteristics.
.
DESIGN: A matched cross-sectional study including a prospective oral questionnaire and retrospective electronic medical record (EMR) review.
.
SETTING: A single hospital in a large academic National Cancer Institute-designated cancer center in Philadelphia, Pennsylvania.
. SAMPLE: 44 Black or Hispanic and 44 Non-Hispanic White newly diagnosed individuals matched on cancer type and age (plus or minus five years).
.
METHODS: Participants answered a questionnaire to capture self-reported opportunity for CCT participation, sociodemographic information, and cancer type. With consent, the authors completed a retrospective review of the EMR to assess eligibility and collect cancer stage and performance status.
. MAIN RESEARCH VARIABLES: Opportunity and eligibility for CCT participation.
.
FINDINGS: Most participants (78%) had no opportunity for participation and were ineligible for all available trials. No differences were noted in opportunity for participation or eligibility based on race or ethnicity. Participants with late-stage disease were more likely to have opportunity and be eligible for CCT participation (p = 0.001). Those with private insurance were less likely to have opportunity for participation (p = 0.05).
.
CONCLUSIONS: Limited trial availability and ineligibility negatively influenced opportunity for CCT participation for all populations. Levels of under-representation for CCT participation likely vary within and across sociodemographic and disease characteristics, as well as across healthcare settings.
. IMPLICATIONS FOR NURSING: The unique roles of nurse navigators and advanced practice nurses can be leveraged to increase opportunities for CCT participation for all populations.

Entities:  

Keywords:  clinical trial; minorities

Mesh:

Year:  2016        PMID: 26679445      PMCID: PMC5934287          DOI: 10.1188/16.ONF.57-66

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  27 in total

Review 1.  Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trials.

Authors:  J G Ford; M W Howerton; S Bolen; T L Gary; G Y Lai; J Tilburt; M C Gibbons; C Baffi; R F Wilson; C J Feuerstein; P Tanpitukpongse; N R Powe; E B Bass
Journal:  Evid Rep Technol Assess (Summ)       Date:  2005-06

Review 2.  Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review.

Authors:  Jean G Ford; Mollie W Howerton; Gabriel Y Lai; Tiffany L Gary; Shari Bolen; M Chris Gibbons; Jon Tilburt; Charles Baffi; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

3.  A matter of race: early-versus late-stage cancer diagnosis.

Authors:  Beth A Virnig; Nancy N Baxter; Elizabeth B Habermann; Roger D Feldman; Cathy J Bradley
Journal:  Health Aff (Millwood)       Date:  2009 Jan-Feb       Impact factor: 6.301

4.  The impact of insurance on access to cancer clinical trials at a comprehensive cancer center.

Authors:  Justin F Klamerus; Suanna S Bruinooge; Xiaobu Ye; Mandi L Klamerus; Dorothy Damron; Dina Lansey; John C Lowery; Luis A Diaz; Jean G Ford; Norma Kanarek; Charles M Rudin
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

5.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.

Authors:  Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

6.  Increasing minority patient participation in cancer clinical trials using oncology nurse navigation.

Authors:  Dennis Ricky Holmes; Jacquelyn Major; Doris Efosi Lyonga; Rebecca Simone Alleyne; Sheilah Marie Clayton
Journal:  Am J Surg       Date:  2011-10-13       Impact factor: 2.565

7.  Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center.

Authors:  Michael S Simon; Wei Du; Lawrence Flaherty; Philip A Philip; Patricia Lorusso; Cheryl Miree; Daryn Smith; Diane R Brown
Journal:  J Clin Oncol       Date:  2004-04-13       Impact factor: 44.544

8.  Participation in cancer clinical trials: why are patients not participating?

Authors:  Margaret M Byrne; Stacey L Tannenbaum; Stefan Glück; Judith Hurley; Michael Antoni
Journal:  Med Decis Making       Date:  2013-07-29       Impact factor: 2.583

9.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  The bottleneck effect in lung cancer clinical trials.

Authors:  Luis E Gonzalez; Steven K Sutton; Christie Pratt; Matthew Gilbertson; Scott Antonia; Gwendolyn P Quinn
Journal:  J Cancer Educ       Date:  2013-09       Impact factor: 2.037

View more
  5 in total

1.  Before Consent: Qualitative Analysis of Deliberations of Patients With Advanced Cancer About Early-Phase Clinical Trials.

Authors:  Sarah B Garrett; Thea M Matthews; Corey M Abramson; Christopher J Koenig; Fay J Hlubocky; Christopher K Daugherty; Pamela N Munster; Daniel Dohan
Journal:  JCO Oncol Pract       Date:  2019-10-11

2.  Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.

Authors:  Yan-Ting Chen; Erik T Valent; Erik H van Beers; Rowan Kuiper; Stefania Oliva; Torsten Haferlach; Wee-Joo Chng; Martin H van Vliet; Pieter Sonneveld; Alessandra Larocca
Journal:  Int J Lab Hematol       Date:  2021-08-26       Impact factor: 3.450

3.  Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials.

Authors:  Andrea N Riner; Selamawit Girma; Vignesh Vudatha; Nitai Mukhopadhyay; Nevena Skoro; Tamas S Gal; Devon C Freudenberger; Kelly M Herremans; Thomas J George; Jose G Trevino
Journal:  J Clin Oncol       Date:  2022-03-22       Impact factor: 50.717

4.  The role of functional, social, and mobility dynamics in facilitating older African Americans participation in clinical research.

Authors:  Eve T Shapiro; Jay T Schamel; Kimberly A Parker; Laura A Randall; Paula M Frew
Journal:  Open Access J Clin Trials       Date:  2017-04-07

5.  Barriers to non-small cell lung cancer trial eligibility.

Authors:  Jeffrey J Hardesty; Norma F Kanarek
Journal:  Contemp Clin Trials Commun       Date:  2017-11-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.